Holen Sie sich die Stockscreener-App
0.9708
3.88%
-0.0392
Handel nachbörslich:
1.01
0.0392
+4.04%
Schlusskurs vom Vortag:
$1.01
Offen:
$1
24-Stunden-Volumen:
1.28M
Relative Volume:
0.88
Marktkapitalisierung:
$111.96M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.5884
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
-2.92%
1M Leistung:
-10.94%
6M Leistung:
+7.54%
1J Leistung:
-71.86%
1-Tages-Spanne:
$0.961
$1.00
1-Wochen-Bereich:
$0.9403
$1.03
52-Wochen-Spanne:
$0.6611
$3.795
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Vergleichen Sie FATE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
0.9708 | 116.48M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
Fate Therapeutics Inc. stock daily chart insightsJuly 2025 Selloffs & Weekly Watchlist for Consistent Profits - newser.com
Stem Cell Co. Beats Investor Suit Over Failed Janssen Collab - Law360
Fate Therapeutics Gets J&J Partnership Class Action Tossed Again - Bloomberg Law News
Top chart patterns to watch in Fate Therapeutics Inc.Insider Buying & AI Enhanced Trade Execution Alerts - newser.com
Evaluating Fate Therapeutics Inc. with trendline analysisWeekly Trend Summary & AI Driven Price Predictions - newser.com
Fate Therapeutics, Inc. $FATE Shares Bought by Acadian Asset Management LLC - MarketBeat
Applying big data sentiment scoring on Fate Therapeutics Inc.2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com
Options Flow: Can Fate Therapeutics Inc ride the EV waveIndex Update & Weekly Setup with ROI Potential - خودرو بانک
Aug PreEarnings: Is Fate Therapeutics Inc. subject to activist investor interestTrend Reversal & Fast Entry High Yield Stock Tips - خودرو بانک
Will Fate Therapeutics Inc. rebound enough to break even2025 Technical Overview & Daily Stock Trend Watchlist - newser.com
Aug PostEarnings: Is Fate Therapeutics Inc in a bullish channel2025 Retail Activity & Consistent Growth Equity Picks - خودرو بانک
Using Ichimoku Cloud for Fate Therapeutics Inc. technicalsEarnings Beat & Technical Entry and Exit Alerts - newser.com
Insider Buy: What is the dividend yield of Fate Therapeutics IncQuarterly Portfolio Review & AI Driven Stock Price Forecasts - khodrobank.com
MACD Signal: Is Fate Therapeutics Inc subject to activist investor interest2025 Macro Impact & Fast Moving Market Watchlists - khodrobank.com
Signal strength of Fate Therapeutics Inc. stock in tech scannersStop Loss & Accurate Entry/Exit Alerts - newser.com
Breakout Zone: Is Fate Therapeutics Incs ROIC above industry averageGlobal Markets & Real-Time Market Trend Scan - khodrobank.com
Short Covering: Is Fate Therapeutics Inc subject to activist investor interestJuly 2025 Breakouts & Growth Focused Stock Reports - خودرو بانک
Should you wait for a breakout in Fate Therapeutics Inc.2025 Top Decliners & Safe Capital Growth Tips - newser.com
Fed Meeting: Is Fate Therapeutics Inc stock risky to hold nowWeekly Investment Recap & Risk Managed Investment Strategies - خودرو بانک
Portfolio Shifts: Is Fate Therapeutics Inc showing insider buyingMarket Movers & Weekly Stock Performance Updates - خودرو بانک
Analyst Upgrade: Is Fate Therapeutics Inc showing insider buyingWeekly Investment Summary & AI Driven Stock Price Forecasts - khodrobank.com
Trading Recap: Is Fate Therapeutics Inc in a bullish channelJuly 2025 Setups & Free AI Powered Buy and Sell Recommendations - خودرو بانک
Risk Report: Will Fate Therapeutics Inc outperform the market in YEARMarket Movers & Verified Chart Pattern Signals - خودرو بانک
Jacobs Levy Equity Management Inc. Acquires 616,336 Shares of Fate Therapeutics, Inc. $FATE - MarketBeat
What analysts say about Fate Therapeutics Inc stockJuly 2025 Recap & High Yield Stock Recommendations - خودرو بانک
Hedge Fund Bets: Can Fate Therapeutics Inc lead its sector in growth2025 Technical Patterns & Smart Swing Trading Techniques - خودرو بانک
Momentum Shift: Is Fate Therapeutics Inc stock risky to hold now2025 Fundamental Recap & Reliable Breakout Forecasts - خودرو بانک
Activity Recap: What is the dividend yield of Fate Therapeutics Inc2025 Major Catalysts & Safe Capital Allocation Plans - خودرو بانک
Stock Report: Will Fate Therapeutics Inc outperform the market in YEAR2025 Institutional Moves & Technical Buy Zone Confirmation - خودرو بانک
How to read the order book for Fate Therapeutics Inc.Global Markets & Community Shared Stock Ideas - newser.com
Should you hold or exit Fate Therapeutics Inc. nowJuly 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com
Walleye Capital LLC Sells 1,010,806 Shares of Fate Therapeutics, Inc. $FATE - MarketBeat
Nuveen LLC Purchases Shares of 379,088 Fate Therapeutics, Inc. $FATE - MarketBeat
Leerink Partnrs Analysts Raise Earnings Estimates for FATE - MarketBeat
Will Fate Therapeutics Inc. outperform small cap indexesJuly 2025 Chart Watch & Comprehensive Market Scan Reports - Lancaster City Council
RSI + MACD Show Convergence for Fate Therapeutics Inc.2025 Dividend Review & Weekly Stock Breakout Alerts - beatles.ru
Analysts Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $3.30 - MarketBeat
Price Floor Holding on Fate Therapeutics Inc. — Rebound PossibleJuly 2025 Summary & Verified Short-Term Trading Plans - beatles.ru
Using data models to predict Fate Therapeutics Inc. stock movementEarnings Recap Summary & Consistent Return Investment Signals - Newser
Volume spikes in Fate Therapeutics Inc. stock – what they meanGlobal Markets & Risk Adjusted Swing Trade Ideas - Newser
Heatmap analysis for Fate Therapeutics Inc. and competitorsJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - Newser
Visual trend scoring systems applied to Fate Therapeutics Inc.Market Trend Report & AI Optimized Trading Strategy Guides - Newser
What MACD and RSI say about Fate Therapeutics Inc.July 2025 Macro Moves & Reliable Volume Spike Trade Alerts - Newser
Leerink Partners Sticks to Its Buy Rating for Fate Therapeutics (FATE) - The Globe and Mail
Layoff Tracker: AC Immune To Cut 30% of Workforce - BioSpace
Can technical indicators confirm Fate Therapeutics Inc.’s reversalSwing Trade & Stock Market Timing Techniques - Newser
What are analysts’ price targets for Fate Therapeutics Inc.2025 Market Overview & Smart Swing Trading Alerts - خودرو بانک
Key metrics from Fate Therapeutics Inc.’s quarterly dataEarnings Recap Summary & Safe Investment Capital Preservation Plans - Newser
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):